This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. The 8th edition of the American Joint Committee on Cancer Tumor-Node-Metastasis (AJCC-TNM) staging system for esophageal cancer (EC) retained the definition of N categories based on the number of metastatic lymph nodes (LN). However, it is difficult to accurately determine the number of metastatic LN without surgery. This study aimed to propose a revision to the N categories of the 8th edition AJCC-TNM staging system that makes staging easier to perform and better represents the prognosis of non-surgical esophageal squamous cell cancer (ESCC). We retrospectively reviewed the data of 336 patients with ESCC. The revised N categories were based on the anatomic regions of LN metastasis (cervix, thorax and abdomen). Survival was analyzed using the Kaplan-Meier method and compared using the log-rank test. Multivariate analyses were performed using the Cox proportional hazard model. Survival differences were adequately discriminated when the revised N categories were used. Subgroup analyses by T stage showed significant difference in overall survival between the revised N categories. Multivariate analyses demonstrated that T stage, revised N category, age, sex and treatment modality were independent risk factors, with the revised N category being the most significant variable. The revised N categories determined in this study can be used to fill gaps in the staging system for patients with non-surgical ESCC, which can help clinicians to make better treatment decisions and more effectively predict patient prognoses. Future large-scale studies are required to validate these results.
| INTRODUC TI ON
Esophageal cancer (EC) is one of the most common highly aggressive malignancies worldwide, including in China, and it has a dismal prognosis. 1, 2 In 2015, approximately 477 900 new cases of esophageal cancer and 375 000 esophageal cancer-related deaths were reported in China. 3 These new cases of EC and EC-related deaths in China account for the majority of EC cases worldwide. [2] [3] [4] In addition, an estimated 90% of patients with EC in China were diagnosed with squamous cell cancer. 5, 6 Accordingly, esophageal squamous cell cancer (ESCC) is sometimes considered to be a characteristic disease epidemic in China. Nevertheless, the 8th edition of the American Joint Committee on Cancer TumorNode-Metastasis (AJCC-TNM) staging system for EC launched on January 2018 was based on the Worldwide Esophageal Cancer
Collaboration database, which includes only 19.4% (4401/22 654)
of Asian patients. [7] [8] [9] [10] Thus, the accumulation of more data from Asian patients, particularly Chinese patients with ESCC, is essential to establish a more accurate staging system for EC.
Moreover, the main drawback of the 8th edition of the AJCC-TNM staging system is that it is generally not applicable for patients with non-surgical EC because it is difficult to accurately evaluate lymph node (LN) metastasis without surgery. Therefore, an easyto-perform and effective pre-therapeutic prognostic clinical staging system for non-surgical EC needs to be established. In a study performed by An et al, 11 patients with EC who underwent 3-field lymphadenectomy were divided into 4 groups according to the fields of LN involved (no LN metastasis; 1-field LN metastasis; 2-field LN metastasis; and 3-field LN metastasis); a significant difference in 5-year survival was reported among the 4 groups. Shimada et al 12 also found a significant decrease in the 5-year survival rates of patients with EC who underwent 3-field lymphadenectomy as the number of fields with LN metastasis increased.
In this retrospective study, using data from a cohort of Chinese patients treated in 2 institutions, we propose a revision of the N categories in the 8th edition of the AJCC-TNM staging system based on the anatomic regions of LN metastasis (cervix, thorax and abdomen) that makes staging easier to perform and better represents the prognosis of non-surgical ESCC. Tumor staging was performed according to the 8th edition of the AJCC staging system for ESCC. We divided the esophageal lymphatic drainage into 3 groups based on the anatomic regions: cervical, thoracic or abdominal LN (Table 1 ). We then classified the patients into in China, 13 we mainly used CT for the diagnosis of metastatic lymph nodes. Lymphadenectasis is the criterion for cancerous metastasis.
| MATERIAL S AND ME THODS

| Patients
The general criterion is that the short-axis diameter of LN is more than 10 mm on the CT images, but if the long-axis diameter of the paraesophageal, tracheoesophageal sulcus, pericardial angle or abdominal LN is more than 5 mm, cancerous metastasis is also considered to be positive.
| Treatment protocols
External beam radiotherapy was performed with intensity- 
| Follow-up
In our study, all patients were followed up every 3 months for the first 2 years, every 6 months until 5 years, and then annually thereafter. The regular follow-up protocol included physical, laboratory, imaging and endoscopic examination for assessing recurrence or metastasis. Overall survival (OS) was defined as the time between the date of the beginning of radiotherapy and date of death or last follow-up. All patients were followed up by phone calls until the end of May 2018. Data of surviving patients were censored on the day of the last contact.
| Statistical analysis
The survival rate was calculated using the Kaplan-Meier method, and the log-rank test was used to assess the survival differences between groups. All variables that achieved significance (P < .1) in univariate analyses were enrolled in a multivariate Cox proportional hazards regression model. A 2-sided probability value of <.05 was considered significant. All statistical analyses were performed using SPSS 17.0 software (SPSS, Chicago, IL, USA).
| RE SULTS
| Demographic and clinicopathological characteristics
A total of 336 patients (263 men and 73 women) with a median age of 63 years (range: 38-79 years) were enrolled in this study. Of Table 2 . (Table 3) .
| Univariate and multivariate analyses of prognostic factors
Kaplan-Meier survival curve analysis based on the revised N category and modified TNM staging system indicated that they had good discriminatory ability in each subgroup (P < .001 for all; Figure 1A ,B). Both showed a relatively ordered monotonic distribution of survival.
To evaluate the utility of the revised N category for predicting survival in different T stages, we performed a stratified analysis in the T2, T3 and T4 subgroups based on the 8th edition of the AJCC staging system. We excluded cases with T1 stage for subgroup analysis because the group size was too small (n = 3). In the T2 subgroup, survival could be distinguished between patients F I G U R E 3 Survival curves for patients who underwent radiotherapy alone (A) and chemoradiotherapy (B) stratified according to the revised N categories with the revised N categories (P < .001; Figure 2A ). Similar results were also observed in the T3 and T4 subgroup (P < .001 for all; Figure 2B ,C).
Subsequently, we also explored the utility of the revised N category in patients who were stratified according to whether they received chemotherapy. These results showed that, in both the radiotherapy alone and chemoradiotherapy subgroup, survival could be well discriminated between patients with the revised N categories (P < .001 for all; Figure 3A ,B).
Furthermore, considering that the condition of LN involved varied both in the revised N1 and N2 categories, we evaluated the survival differences between different anatomic regions of LN metastasis in the N1 and N2 subgroups. There were no differences in survival between patients with different anatomic regions of LN metastasis in either the N1 or N2 subgroup, which shows that the revised N categories are reasonable (P = .747 for N1 subgroup and P = .769 for N2
subgroup; Figure 4A ,B).
| D ISCUSS I ON
An accurate cancer clinical staging system is important for patient stratification, treatment protocol decisions, prognosis assessment and comparison of treatment efficacy from different institutions worldwide. Considering the status of LN metastasis is a critical prognostic factor for patients with EC. [14] [15] [16] In the 7th edition of the AJCC-TNM staging system, released in 2009, the node classification system was changed from being determined by the presence or absence of LN involvement to the number of metastatic LN; this appears to have more clinical significance than the criteria in the previous edition. [17] [18] [19] However, the 7th edition TNM staging for esophageal cancer is also pathological and not applicable for non-surgical EC. Clinically, surgery is not an option for many patients with EC who have a locoregional disease extension or are ineligible for surgery due to reasons such as older age or cardiopulmonary insufficiency. Some patients may also refuse surgery for personal reasons.
F I G U R E 4 Survival curves for the revised N1 (A) and N2 (B) patients stratified by different anatomic regions of involved lymph node Therefore, it is important to obtain an appropriate cancer clinical stage system for non-surgical EC. for 2 fields and 11% for 3 fields of LN metastasis. The survival curves in our study also support that the revised N category and modified TNM staging system can better stratify patients, particularly patients with non-surgical ESCC. The revised N category divides the esophageal lymphatic drainage into 3 groups according to anatomic region, which is simple and practical, and the anatomical position is easy to determine; thus, it is suitable for clinical application.
To the best of our knowledge, this is the first study to propose a revised N category based on the anatomic regions of LN metastasis and a modified version of the 8th edition of the AJCC-TNM staging system in patients with non-surgical ESCC. Our study was conducted in 2 institutions, thus avoiding the possible limitations of a single-center setting and suggesting that our conclusions may be more generalizable. However, the present study has several limitations. First, this is a retrospective study with a relatively small patient size. Second, the small number of patients in some subgroups, especially in the T1 subgroup, may limit statistical power.
Third, our study has relatively low 3-year and 5-year OS rates. Some patients cannot undergo surgery due to advanced stage or old age. 
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